Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor
JoAnne Foody, MD, Robin S. Turpin, PhD, Beni A. Tidwell, BS, Debra Lawrence, PhD, Kathy L. Schulman, MS
Gout is a metabolic disorder that causes flares of arthritis in the joints and occurs with the onset of inflammation as a result of excess serum uric acid in the blood (ie, hyperuricemia) and the deposition of crystals in tissue.
The Growing Role of Real-World Evidence in Clinical Decision-Making
Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide
The Relative Burden of Menopausal and Postmenopausal Symptoms versus Other Major Conditions: A Retrospective Analysis of the Medical Expenditure Panel Survey Data
Annlouise R. Assaf, PhD, Andrew G. Bushmakin, MS, Nina Joyce, PhD, Michael J. Louie, MD, MPH, MSc, Michael Flores, MPH, Margaret Moffatt, MPH
Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas
Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes
Kelvin Lingjet Tran, DO, Young In Park, DO, Shalin Pandya, DO, Navin John Muliyil, DO, Brandon David Jensen, DO, Kovin Huynh, DO, Quang T. Nguyen, DO, FACP, FACE, FTOS
It is estimated that 29.1 million people or 9.3% of the US population have diabetes, which contributes to considerable medical and financial burden.
The GLP-1 Receptor Agonists Are Cost-Effective for the Treatment of Type 2 Diabetes
Todd Williamson, MsC, Rajesh Kamalakar, MS, Augustina Ogbonnaya, MPH, Erin A. Zagadailov, PharmD, MS, Michael Eaddy, PharmD, PhD, Charlie Kreilick, MBA
Multispecialty Rating of Evidence-Based Conditions for Intravenous Immunoglobulin Therapy Using a 3-Axis Prioritization Algorithm
Jordan S. Orange, MD, PhD, Matt Johnson, BA, Barbara Lennert, RN, BSN, MAOM, Katarzyna Shields, PharmD, MBA, BCOP, BCPS, Michael Eaddy, PharmD, PhD
Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy
Dominic Pilon, MA, Ajay S. Behl, PhD, Lorie A. Ellis, PhD, Marie-Noëlle Robitaille, MA, Patrick Lefebvre, MA, Nancy A. Dawson, MD
Comparing Healthcare Utilization and Costs Among Medicaid-Insured Patients with Chronic Noncancer Pain with and without Opioid-Induced Constipation: A Retrospective Analysis
Tope Olufade, PhD, MPH, Amanda M. Kong, MPH, Nicole Princic, MS, Paul Juneau, MS, Rucha Kulkarni, MPH, Kui Zhang, MD, Catherine Datto, MD, MS
Chronic noncancer pain is a common and debilitating condition that affects approximately 30% of adults in the United States. The management of chronic pain is primarily aimed at relieving the pain and improving physical and emotional functions, although these are not achieved in a substantial number of patients.
The Opioid Epidemic: Healthcare Utilization and Cost Considerations
Page 1 of 11
Results 1 - 10 of 104
Results 1 - 10 of 104